BR112021019070A2 - Ligantes de pseudoquinase tyk2 - Google Patents

Ligantes de pseudoquinase tyk2

Info

Publication number
BR112021019070A2
BR112021019070A2 BR112021019070A BR112021019070A BR112021019070A2 BR 112021019070 A2 BR112021019070 A2 BR 112021019070A2 BR 112021019070 A BR112021019070 A BR 112021019070A BR 112021019070 A BR112021019070 A BR 112021019070A BR 112021019070 A2 BR112021019070 A2 BR 112021019070A2
Authority
BR
Brazil
Prior art keywords
ligands
tyk2 pseudokinase
tyk2
pseudokinase ligands
disorders
Prior art date
Application number
BR112021019070A
Other languages
English (en)
Inventor
Jason Harris
John Nuss
Raju Mohan
Shendong Yuan
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of BR112021019070A2 publication Critical patent/BR112021019070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

ligantes de pseudoquinase tyk2. são descritos nesse relatório descritivo ligantes de pseudoquinase tyk2 e métodos de utilização de ligantes de pseudoquinase tyk2 no tratamento de doenças, distúrbios ou condições. também são descritas nesse relatório descritivo composições farmacêuticas que contêm esses compostos.
BR112021019070A 2019-03-26 2020-03-25 Ligantes de pseudoquinase tyk2 BR112021019070A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824144P 2019-03-26 2019-03-26
PCT/US2020/024746 WO2020198379A1 (en) 2019-03-26 2020-03-25 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
BR112021019070A2 true BR112021019070A2 (pt) 2022-02-15

Family

ID=72612101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019070A BR112021019070A2 (pt) 2019-03-26 2020-03-25 Ligantes de pseudoquinase tyk2

Country Status (13)

Country Link
US (2) US11780842B2 (pt)
EP (1) EP3946350A4 (pt)
JP (1) JP2022529311A (pt)
KR (1) KR20220004641A (pt)
CN (1) CN113874021A (pt)
AU (1) AU2020247990A1 (pt)
BR (1) BR112021019070A2 (pt)
CA (1) CA3134814A1 (pt)
EA (1) EA202192625A1 (pt)
IL (1) IL286635A (pt)
MX (1) MX2021011723A (pt)
SG (1) SG11202110523XA (pt)
WO (1) WO2020198379A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870579A4 (en) 2018-10-22 2022-10-19 Alumis Inc. TYK2 INHIBITORS AND THEIR USES
CN113811534A (zh) * 2019-03-11 2021-12-17 埃斯克疗法股份有限公司 Tyk2抑制剂和其用途
CN113874021A (zh) 2019-03-26 2021-12-31 温缇克斯生物科学公司 Tyk2假激酶配体
TW202128698A (zh) 2019-11-08 2021-08-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體
WO2022117090A1 (zh) * 2020-12-03 2022-06-09 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2516824A1 (en) 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
EP2417138B1 (en) 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
HUE035337T2 (en) * 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA46620A (fr) 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
TW202321243A (zh) 2017-03-08 2023-06-01 美商林伯士拉克許米公司 Ｔｙｋ２抑制劑之生產方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
US20220135567A1 (en) 2019-02-07 2022-05-05 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
CN113811534A (zh) * 2019-03-11 2021-12-17 埃斯克疗法股份有限公司 Tyk2抑制剂和其用途
CN113874021A (zh) 2019-03-26 2021-12-31 温缇克斯生物科学公司 Tyk2假激酶配体
TW202128698A (zh) 2019-11-08 2021-08-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體

Also Published As

Publication number Publication date
JP2022529311A (ja) 2022-06-21
US20220169651A1 (en) 2022-06-02
EP3946350A1 (en) 2022-02-09
WO2020198379A1 (en) 2020-10-01
SG11202110523XA (en) 2021-10-28
CN113874021A (zh) 2021-12-31
KR20220004641A (ko) 2022-01-11
CA3134814A1 (en) 2020-10-01
US11780842B2 (en) 2023-10-10
EP3946350A4 (en) 2022-09-07
US20230406858A1 (en) 2023-12-21
IL286635A (en) 2021-10-31
EA202192625A1 (ru) 2022-03-21
AU2020247990A1 (en) 2021-11-11
MX2021011723A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112019000692A8 (pt) Moduladores de somatostatina e usos destes
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
EA201990400A1 (ru) Соединения и композиции и их применение
BR112022000855A2 (pt) Moduladores de nlrp3
BR112021022380A2 (pt) Inibidores de jak
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
EA201990399A1 (ru) Соединения, композиции и их применение
BR112021014566A2 (pt) Moduladores de gpr35